BMS Phase III Camzyos trial misses endpoints

15 April 2025

US pharma major Bristol Myers Squibb (NYSE: BMY) yesterday disclosed that its Phase III ODYSSEY-HCM trial of Camzyos (mavacamten) did not meet its primary endpoints for treating non-obstructive hypertrophic cardiomyopathy (nHCM).

The ODYSSEY-HCM trial, which enrolled 580 adults with symptomatic non-obstructive HCM, did not demonstrate significant improvement versus placebo on the Kansas City Cardiomyopathy Questionnaire – Clinical Summary Score (KCCQ-23 CSS) or peak oxygen consumption (pVO2) from baseline to 48 weeks.

In after-hours trading, Bristol Myers shares declined 1.5% to $50.59, while rival in the sector Cytokinetics (Nasdaq: CYTK) stock fell 2.5% to $38.83. The trial failure represents a disappointment, but BMS has additional pipeline readouts to watch in 2025.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK